| pubmed-article:15850831 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15850831 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:15850831 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15850831 | lifeskim:mentions | umls-concept:C1955926 | lld:lifeskim |
| pubmed-article:15850831 | lifeskim:mentions | umls-concept:C0085187 | lld:lifeskim |
| pubmed-article:15850831 | lifeskim:mentions | umls-concept:C1444754 | lld:lifeskim |
| pubmed-article:15850831 | lifeskim:mentions | umls-concept:C0935989 | lld:lifeskim |
| pubmed-article:15850831 | lifeskim:mentions | umls-concept:C1148756 | lld:lifeskim |
| pubmed-article:15850831 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:15850831 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15850831 | pubmed:dateCreated | 2005-4-26 | lld:pubmed |
| pubmed-article:15850831 | pubmed:abstractText | Imatinib mesylate is a novel tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome positive (Ph+) leukemia and other malignancies. In previous studies, we found significant telomere shortening in Ph+ cells from patients with chronic myeloid leukemia (CML). Interestingly, imatinib treatment was found to lead to a normalization of previously shortened telomere length in CML patients. Based on recent reports demonstrating that c-ABL phosphorylates hTERT and thereby inhibits hTERT activity, a direct effect of imatinib on hTERT activity leading to telomere elongation in BCR-ABL-positive cells has been proposed by others. Such an effect could be of potential importance for telomere maintenance in Ph+ cells by facilitating clonal selection and progression of the disease to blast crisis. | lld:pubmed |
| pubmed-article:15850831 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15850831 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15850831 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15850831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15850831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15850831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15850831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15850831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15850831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15850831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15850831 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15850831 | pubmed:month | May | lld:pubmed |
| pubmed-article:15850831 | pubmed:issn | 0301-472X | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:DuysterJustus... | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:KanzLotharL | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:LippHans-Pete... | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:BokemeyerCars... | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:BrümmendorfTi... | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:FellenbergJör... | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:HartmannUlrik... | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:BalabanovStef... | lld:pubmed |
| pubmed-article:15850831 | pubmed:author | pubmed-author:ZieglerPatric... | lld:pubmed |
| pubmed-article:15850831 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15850831 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:15850831 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15850831 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15850831 | pubmed:pagination | 542-9 | lld:pubmed |
| pubmed-article:15850831 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:meshHeading | pubmed-meshheading:15850831... | lld:pubmed |
| pubmed-article:15850831 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15850831 | pubmed:articleTitle | Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. | lld:pubmed |
| pubmed-article:15850831 | pubmed:affiliation | Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany. | lld:pubmed |
| pubmed-article:15850831 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15850831 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
